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ROLE OF PLEURAL FLUID BIOMARKERS-ADA, ADA2 & 
INTERFERON GAMMA IN THE DIAGNOSIS OF 
TUBERCULOUS PLEURAL EFFUSION. 
 
1. AIMS & OBJECTIVES OF THE STUDY: 
a) To study the role of pleural fluid biomarkers- ADA, ADA2 
and Interferon gamma in the diagnosis of tuberculous pleural 
effusion. 
 
b) To study the combination of biomarkers in the diagnosis of 
pleural tuberculosis. 
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2. REVIEW OF LITERATURE: 
a. Introduction:  
Tuberculosis (TB) is an ancient disease caused by Mycobacterium 
tuberculosis. The infection is transmitted from person to person by 
droplets. It is one of the most communicable diseases which are 
prevalent in the community.  
TB is the most common opportunistic infection in human 
immunodeficiency virus (HIV) infected patients. The risk of 
acquiring TB infection in life time is 10% in a non HIV infected 
individual and 50% in a HIV infected individual.(1) The other 
challenge is the management of multidrug resistant tuberculosis 
(MDR TB). In MDR TB, the TB bacilli are resistant to the 
effective first line anti tuberculous drugs, isoniazid and rifampicin. 
(1) The Extensively drug resistant tuberculosis (XDR-TB) is 
MDR-TB and in addition resistant to fluroquinolones and 
Injectables.  
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b. History of tuberculosis: 
Tuberculosis is considered one of the ancient diseases in the pre-
historic era.  It was an epidemic in the eighteenth and nineteenth 
century gaining the name  ―Captain among these men of death‖ 
(2). Tuberculosis caused the ―white plague‖ in seventeenth and 
eighteenth century in Europe(3). In 1882, Dr.Robert Koch 
discovered the tubercle bacilli. The administration of tuberculin 
protein and demonstrating tuberculin sensitivity was started by 
Clemens Freiherr von Pirquuet in 1907. (2) The practice of open 
air treatment and sanatorium was started in 1907.In 1921, the first 
BCG vaccine was administered to aninfant bornof a mother dying 
of pulmonary tuberculosis and the infant survived.A mass BCG 
vaccination was conducted in Europe by the UNICEF and Danish 
Red Cross. This was the first disease control program conducted 
by an agency of the world health organization. (2) 
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The first antituberculous drugs Para-amino salicylic acid (PAS) 
and Thiosemicarbazone were discovered in the 1940’s but had 
disappointing results due to the bacteriostatic nature of the drugs. 
Streptomycin was discovered in 1944 was used to treat TB and 
showed promising results. Then newer drugs like Isoniazid(INH) 
and Rifamycin’s were discovered in 1952 and 1957 
respectively.(2) The discovery of newer effective 
chemotherapeutic drugs led to the treatment of TB in domiciliary 
basis.  
c. Microbiology of Mycobacterium tuberculosis:  
Tuberculosis is caused by Mycobacterium tuberculosis (MTB). It 
is also called as Koch’s bacilli(4). It belongs to the genus 
Mycobacterium and the most important member of the genus is 
Mycobacterium tuberculosis. The microbiological nature of 
Mycobacterium tuberculosis is its aerobic, non motile, non spore 
forming bacillus. It has a cell wall with high lipid content which 
accounts for the impermeability and resistance to antimicrobial 
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agents. (5) The MTB are grown in Middlebrook’s medium which 
is an agar based medium and Lowenstein-Jensen’s medium which 
is an egg based medium. These organisms cannot be stained by the 
routine gram stain. These organisms are acid fast and are stained 
using the Zeil-Neelsen stain using carbol fuchsin(3) 
d. Pathogenesis:  
The MTB targets the host macrophages, which are the key 
mediators for innate and adaptive immune response. The organism 
gains access into the macrophage by the process of receptor 
mediated phagocytosis. The ability of the macrophages to produce 
anti-microbial chemicals like nitric oxide and reactive oxygen 
intermediates is blunted.(5) 
The components of the MTB are recognized by multiple pattern 
recognition receptors on the alveolar macrophages which initiates 
innate immunity. The circulating monocytes migrate across the 
blood vessels to the site of infection in response to the chemokines.  
Within the tissues,  the monocytes differentiate into macrophages 
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and help in the process of ingestion & killing of the organism.(5) 
The macrophages are activated by interferon gamma which is 
secreted by T cells. The interaction between the macrophages and 
T cells is the central in elimination of the organism.  
Adaptive immunity which is regulated by the CD4 and CD8 cells 
arrest the bacterial growth and lead to latent TB infection. It is a 
state of dynamic bacterial and immunological equilibrium and not 
merely a state of bacterial stasis(5) 
The proposed mechanisms for reactivation of latent TB infection 
are qualitative and quantitative defects of CD4 cells and 
therapeutic neutralization of tumour necrosis factor(5).  
e. Diagnostic methods for tuberculosis: 
Sputum microscopy:  
Sputum microscopy and Ziehl Neelsen staining for acid fast bacilli 
is done to any person who has prolonged duration of cough for 2 
weeks or more, with or without symptoms of Tuberculosis.   Two 
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sputum specimens collected on consecutive days. The first sample 
is a spot sample and second being an early morning sample.  A 
patient who is suspected to have extra-pulmonary tuberculosis 
should also undergo sputum examination if he has cough of any 
duration.  The sensitivity of sputum microscopy is 64% and a 
specificity of 98%(6). The advantage of sputum microscopy is its 
simple, rapid and inexpensive. The sensitivity of the test decreases 
if the bacterial load is less than 10,000 organisms per mL sputum 
sample. (7) The paediatric population, HIV co-infected patients 
and in extra pulmonary tuberculosis patients are the other factors 
which affect the sensitivity of sputum microscopy.  
Fluorescent microscopy:   
In Fluorescent microscopy, flurochrome dyes are used to stain. It 
consists of a halogen or high pressure mercury lamp which is the 
light source and is used to excite the dye and florescence.  
Fluorescent microscopy has a higher sensitivity than conventional 
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sputum microscopy by 10%.The higher cost(7) is the major 
limiting factor in fluorescent microscopy. 
 
Culture methods: 
The culture of Mycobacterium tuberculosis is the gold standard for 
the diagnosis of tuberculosis. There are two types of culture media: 
1) Solid medium, 2) Liquid medium. 
The solid medium culture is the Lowenstein-Jensen medium and 
Middle Brook medium. The liquid mediums are the liquid culture 
medium methods with automated incubation and reading systems. 
They are MB/BacT ALERT 3D system and BACTEC MGIT 960 
system.  
Lowenstein-Jensenmedium (LJ medium): 
The LJ mediumis a solid media used for growing Mycobacterium 
tuberculosis and also used for drug susceptibility testing. Its main 
contents are fresh egg and glycerol.  The two advantages of egg 
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based media are: 1) It can support the growth of wide variety of 
Mycobacterial species; 2) Niacin testing can be done on egg 
media. (8) The initial Lowenstein media was modified by Jensen 
by removing Congo red, increasing the concentration of malachite 
green and alternating the citrate & phosphate contents.  The 
median duration of growth to appear in LJ media is about 3 to 6 
weeks for isolation and 1 to 2 weeks for speciation(9).  The major 
disadvantage is the prolonged turn around time for the diagnosis. 
Middle Brook medium:  
It is another solid medium which is used for Mycobacterium 
culture. It uses agar as a primary substrate. The major drawback of 
this medium is the long period for growth, at least 3-4 weeks.(10) 
BACTEC 460:  
This liquid media was found by Deland and Wagner in 1969. It is a 
radiometric technique using 
14 
C- substrate incorporated in the 
growth media. As the bacterium grows, it utilizes the 
14
 C thereby 
releasing 
14 
carbon dioxide which is thereby identified by 
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radiometric technique. It was found that this method had a 15 to 
20% increased culture positivity compared with the conventional 
solid culture media. (10) The limitation with liquid media is risk of 
contamination. Addition ofantimicrobials to the media prevents 
contamination and it was called BACTEC 460TB. The 
antimicrobials added in the culture media are Polymyxin B, 
Amphotericin B, Nalidixic acid, Trimethoprim, Azlocillin and the 
combination is called PANTA formulation. The major 
disadvantage with BACTEC 460TB media is the use of radioactive 
substrate, 
14
C.  Strict handling and disposal measures of 
radioactive substances(10) is required while using this method.  
Mycobacterium growth indicator tube (MGIT):  
The MGIT culture method is a non- radiometric technique 
developed by Becton-Dickson and company. It is a liquid broth 
medium with 7mL of modified Middlebrook 7H9 broth base. The 
medium is further enriched with Oleic acid, albumin, dextrose and 
catalase to form MGIT OADC or MGIT 960 growth supplement to 
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make the medium complete. The sterilization of the medium 
isdone by autoclaving.(10) Except blood, all the samples can be 
processed using MGIT culture method.  The MGIT tube contains 
oxygen quenched flurochrome, tris 4, 7-diphenyl-1, phenonthroline 
ruthenium chloride pentahydrate embedded in silicone at the 
bottom of the tube.  With the bacterial growth, the oxygen is 
utilized and carbon dioxide is released. With depletion of oxygen, 
the flurochrome is not inhibited resulting in fluorescence when 
visualized under ultraviolet rays.  The growth is visualized as non-
homogenous turbidity or small granular or flaky appearance. The 
test is considered negative if there is no growth at 6 weeks (42 
days) and it is considered negative(10). In a study, 9558 extra 
pulmonarysamples were cultured with BACTEC MGIT 960 tube 
and LJ cultures; the sensitivity was 88.8% and 69.3% 
respectively(11). The advantages of MGIT: 1) It does not use 
radioactive substance, 2) There is rapid growth compared to LJ and 
Middlebrook media, 3) The growth can be visualized.  
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Molecular diagnostic methods:  
Line probe assay (LPA):  
In the era of increasing drug resistant TB, the rapid diagnosis and 
initiation of appropriate chemotherapeutic drugs is the key for 
successful treatment.  The conventional culture and drug 
sensitivity methods take 2 to 8 weeks and additional 3 to 6 weeks 
respectively. This led to the emergence of newer diagnostic 
methods using molecular probes and line probe assay is the first of 
its kind.  The line probe assay is a reverse hybridization based 
assay which is used for rapid detection of mutation for INH and 
Rifampicin.  The advantage of LPAs is it has a high sensitivity 
(90-97%) and specificity (≥99%) in detecting resistance to 
Rifampicin and or INH(12).  The LPA is done in specialized lab 
with following areas: 1) pre-amplification area (reagent 
preparation), 2) DNA extraction area( specimen preparation) , 3) 
amplification area( template addition and amplification), 4) Post 
amplification or hybridization/ detection area. The molecular 
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identification of resistance is detected by identifying 81-base pair 
region mutation of rpoB gene and katG gene mutation for 
Rifampicin and INH respectively.  The major steps in LPA are 1) 
NaOH-NALC decontaminated sputum or culture isolates for DNA 
extraction, 2) multiplex PCR on the extracted sample, 3) Reverse 
hybridization where the resistance to Rifampicin and or INH is 
detected on strips. There are newer line probe assays looking at 
gyrA mutations for fluroquinolone resistance(13)From 2010, The 
line probe assay is included by the RNTCP programmefor the 
diagnosis of MDR tuberculosis (14) 
Xpert MTB/Rif:  
Thisis an automated molecular test for Mycobacterium 
tuberculosis and to detect resistance to Rifampicin. The principle 
of the test is hemi-nested real time polymerized chain reaction 
(PCR) and also amplifies MTB sequence of rpoB gene which 
reflects resistance to Rifampicin(15) 
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The Gene Xpert test consists of a plastic catridge which contains 
reagents required for bacterial lysis, nucleic acid extraction, 
amplication and amplicon detection. The initial step is addition of 
bactericidal buffer to sputum sample followed by adding the 
sputum to catridge. The results are obtained after 2 hours.  The 
advantage of this test is quick diagnosis with identifying 
Rifampicin resistance (16)The disadvantages are short half life (18 
months), requires stable electrical supply, annual recalibration, 
ceiling temperature, higher cost.  
Mantoux test/ Tuberculin skin test:  
The tuberculin skin testing is one of the tests used to detect 
tuberculosis infection. It also assesses the status of infection in 
community. The PPD-S is currently used. The Tuberculin(PPD-RT 
23 with Tween 23) at a dose of 5 tuberculin units is administered 
intradermally and the reading is taken after 48 to 72 hours.  The 
preferred site of administration is the volar aspect of left forearm. 
The immunological basis for Mantoux test is delayed 
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hypersensitivity reaction. In sensitized individuals, the T cells 
release lymphokines which cause induration.  
Table 1 showing interpretation of Mantoux test(17) 
5mm or more 10mm or more 15mm or 
more 
Recent contact with TB 
case 
Injectable drug abusers Persons with 
no risk 
factors for 
TB 
HIV positive person Mycobacteriology lab 
personnel 
 
Organ transplant 
recipients 
High risk clinical 
conditions like diabetes 
 
Long term 
corticosteroids 
Infants, children 
exposed to adults in 
high risk categories 
 
 Recent arrivals < 5 
years from high 
prevalence country 
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Table 2  showing false positive and false negative for Mantoux 
test(17): 
False positive False negative 
         Atypical mycobacterial infection Recent TB infection 
BCG vaccination in the past Very old TB infection. 
Wrong method of administration of TST Very young age  
Wrong interpretation Recent vaccination- Measles 
Wrong antigen Wrong administration and 
interpretation 
 Cutaneous anergy 
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Figure1 showing sensitivity of the current diagnostic tests(5) 
Most sensitive tool being automated liquid cultures. 
Automated nucleic acid amplification technique (NAAT) shows a 
compared sensitivity to solid cultures. 
LAMP- Loop mediated amplification. 
TB- Tuberculosis; LED- Light emitting diode. 
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f. Incidence of Tuberculosis: 
Global incidence:  
The global incidence of tuberculosis in 2011 was 8.7 million(18) 
India:  
The incidence in 2011 was 2.2 million and the prevalence was 3.1 
million.(18)The WHO data reveals that 6,88,530 patients were 
detected to have TB and HIV co-infection in 2011  and 2.1% of the 
newly detected cases to be MDR TB(19) 
Tamilnadu:   
The total population covered by RNTCP was 72,100,000 and 
79,830 patients registered under RNTCP for treatment in the year 
2011(18) 
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g. Tuberculous pleural effusion:   
TB pleural effusion is the commonest cause of pleural effusion 
inmany countries including India.  TB pleural effusion is the 
common site for extrapulmonary tuberculosis(20). Extrapulmonary 
tuberculosis has increased in prevalence to four fold with the 
increase in HIV infection. 
h. Incidence of TB pleural effusion:  
Tuberculous pleural effusion varies in incidence from country to 
country. The incidence in United States is 3-5% whereas its 25% in 
Burundi, an East African countryand 20% in South Africa(21). The 
patients with immunocompromised state are more prone to develop 
TB pleural effusion.  The incidence of pleural tuberculosis is 
comparatively high in India and it accounts about 30%(22). 
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i. Pathogenesis of TB pleural effusion: 
TB effusion is described as an acute granulomatous  pleuritis(23). 
It is a sequlae of a recent tuberculous infection within 6 to 12 
weeks. In older individuals, it occurs as classical reactivation 
tuberculosis. There may be no apparent evidence of tuberculosis 
radiographically.  
The pathophysiology of TB pleural effusion is believed to be 
rupture of subpleural caseous focus in the lung into the pleura.  
The other mechanism believed is delayed hypersensitivity 
reaction(21).When tuberculous protein gains access to pleural 
space the delayed hypersensitivity reaction takes place. The 
evidence for delayed hypersensitivity is demonstrated by 
intrapleural administration of tuberculin protein in purified protein 
derivative (PPD) sensitized guinea pigs lead to development of 
exudative pleural effusion(21). Anti lymphocyte serum in 
sensitized guinea pigs suppresses the development of pleural 
effusion. The mycobacterial cultures in the pleural fluid are 
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negative in most of the patients supporting delayed 
hypersensitivity reaction.  
Once the delayed hypersensitivity reaction occurs, the permeability 
of the pleural capillaries increases leading to excessive movement 
of protein into the pleural space and the volume of pleural effusion 
increases.  In addition the clearance of pleural fluid is affected by 
lymphatic obstruction due to lymphocytic pleuritis(21).  
j. Characteristics of TB pleural effusion:  
The aetiology of TB pleural effusion is inflammation and is 
invariably an exudate. The cellular composition of the pleural fluid 
is predominantly lymphocytic. Tuberculous pleural effusion rarely 
presents with pleural fluid eosinophilia (Eosinophil count >10cells) 
but can occur in pneumothorax or with previous 
thoracocentesis(21) 
The effusion can be neutrophilic in a setting of tuberculous 
empyema(24). The pleural fluid glucose may be reduced or at the 
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serum level. The pleural fluid pH is around 7.30 and LDH is 
elevated above serum levels.  
According to an Indian study(23)which looked at the clinico-
radiological and biochemical characteristics of TB pleural 
effusionin 94.34%,pleural fluid protein was >3gm/dL, in 97.44% 
pleural fluid LDH was >200IU/L and in 83.02% pleural fluid 
glucose was <60mg/dL. 
k. Clinical features of TB pleural effusion:  
TB pleural effusion is commonly seen in middle age to older age 
group.  The onset of illness is abrupt in two-third of the patients 
and insidious in rest of the cases. The common symptoms are non-
productive cough (~70%), pleuritic chest pain (~70%)(21). Most of 
the cases have febrile, approximately 15% are afebrile. The pleural 
effusion in usually unilateral and most commonly involves one 
half of the hemithorax(25). After malignancy and pneumonia, 
tuberculosis is the third most common cause for large pleural 
effusion. About 20% of patients have co-existing parenchymal 
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lesions on chest x ray & 80% of patients have parenchymal lesions 
on computed tomography(21). 
l. TB effusion diagnosis:  
The conventional tests used for the diagnosis of pleural 
tuberculosis are pleural fluid microscopy to look for acid fast 
bacilli (AFB), pleural fluid MTB culture, pleural tissue MTB 
culture and histopathological examination of the pleural tissue 
demonstrating granulomatous inflammation(26). The yield of 
pleural fluid microscopy in detecting TB pleural effusion is < 5% 
due to the paucibacillary state.  The sensitivity of pleural fluid 
cultures is low (24-58%) and further limited by the lengthy delay 
in obtaining results (8weeks). The pleural tissue histopathology 
and cultures is the currently available sensitive tool to diagnose 
tuberculous pleural effusion.In addition, pleural biopsy is invasive 
and the yield depends on the skill of the operator with risk of 
complications(26) 
30 
 
In a study where they looked at the yield of induced sputum in TB 
pleural effusion, the sensitivity of induced sputum was 52% when 
compared with 12% for pleural fluid culture(26) 
m. Pleural fluid biomarkers:   
Due to thediagnostic challenges in the diagnosis of tuberculous 
pleural effusion, newer tests and biomarkers are employed to 
improve thediagnostic yield.  
The newer tests are classified as(26):  
1) Non specific inflammatory and immune response markers  
(E.g. ADA, cytokines, neopterin, leptin, complement activation, 
Lysozyme) 
2) Specific markers to immune response 
(E.g. T-cell response to specific antigens- TB SPOT,  
Quantiferon TB Gold;B-cell response – antibody detection. 
3) Detection of MTB nucleic acid sequences by amplification tests. 
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4) Scoring system based on combination of markers.  
 
Adenosine deaminase (ADA):  
ADA is a non-specific marker of inflammation. It is produced and 
released from macrophages, activated lymphocytes and 
neutrophils. ADA1 and ADA2 are the two isoenzymes of ADA. 
ADA2 is released by activated monocytes and 
macrophages(27).ADA2 predominantly contributes to the total 
ADA activity. The accuracy of the test can be improved by 
analyzing isoenzymes. ADA has a sensitivity of 90.8% and 
specificity of  82.8%(28) 
A study looked at ADA and ADA1/ADA ratio which found a 
higher sensitivity and specificity when combining ADA ≥40U/L 
and ADA1/ADA ≤0.42 (29).  
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 ADA ADA1/ADAp 
Sensitivity 88% 100% 
Specificity 92% 98.6% 
Positive predictive value 80% 96.4% 
Negative predictive value 95.7% 100% 
Accuracy  91.2% 99.02%  
Table 3: showing the utility of ADA and ADA1/ADAp in the 
published literature. 
 
Neopterin:   
Neopterin is produced by activated macrophages and it’s a marker 
of Th1 activation. Neopterin levels are found high in tuberculous 
pleural effusion. The sensitivity is 44% and specificity is 85%(26) 
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Leptin: 
Leptin is produced by obese (ob) gene.  Low leptin levels are 
found in active tuberculosis and cancer. But it has a low sensitivity 
and specificity compared to ADA(26) 
 
Interferon gamma:  
The tuberculous infection initiates a cascade of immunological 
reaction and causes Th1 lymphocyte recruitment and release of 
various cytokines(30) Among the various cytokines released 
Interferon gamma is the important cytokine. Among the other 
cytokines like tumour necrosis factor alpha, IL-1β but the cytokine 
with high sensitivity and specificity for tuberculosis is interferon 
gamma. It has a sensitivity of 89% and specificity of 97%.  
In malignant effusions higher levels of other interleukins like IL-8, 
IL-6 and soluble IL-6 receptor and not in TB effusions.(26) 
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Interferon gamma release assay(IGRA):  
The interferon gamma release assays are useful in detecting latent 
Tb infection. Quantiferon TB Gold and T-SPOT TB test are the 
commercially available IGRA’s. The assay detects the release of 
Interferon gamma from the mononuclear cells in response to 
Mycobacterium tuberculosis specific antigen. The T-SPOT TB test 
carries a sensitivity of 95% and specificity of 76% in pleural fluid 
samples(26). The Quantiferon TB Gold test uses the ELISA 
platform and is more amenable to high input and flexibility.  
Advantage of IGRA is it can detect latent TB infection. 
Disadvantage of IGRA: 1) Lacks specificity, 2) Costly. 
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Scoring system based on combination of markers:  
A combination of clinical data and biomarkers are used and also 
found to increase the sensitivity and specificity. A study by Lesley 
et al found that a combination of ADA> 50 IU/L and lymphocyte 
neutrophil ratio of 0.75 or more increases the sensitivity and 
specificity to 88% and 95% respectively(25).  A combination of 
duration of symptoms + protein+ leukocyte count+ lymphocyte 
%+ ADA increased the sensitivity(31). When ADA>40IU/L  
combined with Interferon gamma ≥75pg/mL the specificity 
increased to 100%(32).  When ADA>40IU/L combined with 
ADA1/ADA ratio ≤0.42, the sensitivity increased to 100% and 
specificity to 98.6%. (29)So by combining different parameters the 
sensitivity and specificity in diagnosing pleural tuberculosis. 
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3. METHODOLOGY: 
Inclusion criteria:  
All patients with exudative pleural effusion getting evaluated in 
Christian medical college who are willing to participate (after 
informed consent) were included between the time periods of May 
2012- July 2013.  
Exclusion criteria:   
Patients with proven or suspected malignancy based on imaging or 
outside biopsy.  
Patients not willing to give consent.  
Method of recruitment:   
Patients who present with pleural effusion to the department of 
pulmonary medicine, Christian medical college, Vellore were 
included in the study after obtaining an informed consent.  A total 
of 154 patients were included in the study after obtaining consent. 
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Method of evaluation:   
After recruitment, all patients underwent pleural fluid aspiration 
followed by pleural biopsy (closed or ultrasound guided).  
The pleural fluid samples were sent for cell counts, protein, and 
LDH and mycobacterial cultures. Using the true cut biopsy needle, 
pleural biopsy samples were obtained and the samples were sent 
for mycobacterial culture (LJ medium or MGIT) and 
histopathology.   
A 5mL pleural fluid study sample was collected in a red tube and 
sent to the clinical biochemistry laboratory.  
The sample is then stored at -70degree Celsius.  The study samples 
are stored in deep freezer and pooled followed by analysis. 
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Adenosine deaminase (Total ADA): 
Using the DIAZYME kit, ADA assay was performed; catalog 
number DZ117A-K and universal configuration.  
 The principle of the assay is on enzymatic deamination of 
adenosine to inosine which is converted to hypoxanthine by purine 
nucleoside phosphorylase (PNP)(33).  The results of ADA are 
represented in U/L.  
Adenosine + H2O ADA Inosine + NH3 
Inosine + Pi     PNP      Hypoxanthine+  
                                    Ribose-1-phosphate 
Hypoxanthine+ 2H2O+ O2     XOD   Uric acid +   
                                                              2H2O2 
H2O2+ 4-AA+ EHSPT     POD        2H2O+ Quinone  
                                                                        Dye 
                                                         (λ max 556nm) 
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Adenosine deaminase 1(ADA1): 
Colorimetric method was used to analyze ADA1. The substrate 
adenosine which is used in the estimation of ADA is replaced by 
the substrate 2'-deoxyadenosine(34).   
 
Adenosine deaminase 2 (ADA2): 
The ADA2 activity is calculated from ADA and 2'-deoxyadenosine 
deaminase activities (34).  
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Interferon gamma: 
The Interferon gamma assay is done using ELISA method.  The 
Interferon gamma assay is done using IFN-γ- EASIA kit with 
Proprietary name: DIAsource IFN-γ- EASIA kit, catalogue 
number: KAP1231: 96 tests. It is a solid phase amplified 
immunoassay performed on microtitre plates. The test uses 
monoclonal antibodies against epitopes of interferon gamma (35).  
The pleural fluid sample of 50μL is pipetted into the appropriate 
wells followed by adding 50μL of anti-IFN- γ-HRP conjugate into 
the wells.  The kit is allowed to incubate at room temperature for 2 
hours at 700rpm±100rpm on a horizontal shaker.  The contents in 
the well are aspirated after incubation followed by washing the 
plate thrice by 0.4ml wash solution into each well. This step is 
followed by adding 200μL of freshly prepared Revelation solution 
into each well and incubation for 15 minutes at room temperature 
on a horizontal shaker at 700rpm±100rpm. After 15 minutes, 50μL 
stop solution is added into each well. The absorbencies between 
41 
 
450nm and 490nm are read within 3 hours and the results are 
calculated.  
Sample size calculation: 
Data collected from the patients attending the pulmonary 
medicine,where the investigator is posted.  
Sampling strategy: 
Sample size is calculated from the formula 4pq/d2. From previous 
studies, sensitivity and specificity (p) was found to be 90% and 
precision of the estimate (d) was kept at ± 8 for the calculation of 
95% confidence interval (CI). With these values, we calculated a 
sample size of 80 patients with TB effusions. It is hoped that 
around 200 subjects with exudative pleural effusion will need to be 
recruited to obtain this sample size. 
 
 
 
42 
 
4. Data analysis: 
The data was analyzed for demographic details, the biochemical 
parameters and the pleural fluid parameters- cell counts, protein, 
lactate dehydrogenase (LDH), microbiological variables like 
pleural fluid culture and pleural biopsy culture. The pleural fluid 
biomarkers- adenosine deaminase (ADA), ADA1, ADA2, 
Interferon gamma) are analyzed separately to look for role in 
diagnosing pleural tuberculosis.  
          Statistical analysis:  
The frequencies and percentages are calculated for the biomarkers-
ADA, ADA2 and interferon gamma. The mean age and standard 
deviation of age is calculated. The sensitivity, specificity, PPV, 
NPV analysis of ADA, ADA2, and Interferon gamma is done 
using ROC curve analysis. The area under the curve is also 
estimated. The mean ADA, ADA2, Interferon gamma was 
calculated.   
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5. RESULTS: 
The total number of 154 patients was included in the study during 
the period of May 2012- July 2013. The patients with outside 
diagnosis of malignancy or radiological evidence of malignancy 
were excluded. The enrolled patients underwent pleural aspiration 
and pleural biopsy and the study pleural fluid sample was analyzed 
for biomarkers- ADA, ADA1, ADA2 and interferon gamma.  
Table 4: showing the demographic details of patients with 
pleural effusion. 
 
Patient characteristics Total patients= 154 
Age, years 44.8 
Male 114(74.03)) 
Female 40(25.97) 
Unilateral 146(94) 
Bilateral 8(6) 
HIV infection 1 (0.64) 
Sputum positive for TB 2(1.2) 
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Demographic details (Table 4): 
Among the 154 patients with pleural effusion, male were 74.03% 
(n=114) and female were 25.97% (n=40%). The mean age at 
presentation was 44.8 years. The clinical presentation was mostly 
unilateral pleural effusion, 94%.  One patient had HIV infection 
and two patients had concomitant pulmonary tuberculosis based on 
sputum examination. 
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Age distribution of diseases: (Fig 2) 
Figure 2 shows the age distribution among the study patients. The 
mean age group of patients with tuberculous pleural effusion is 39 
years. The older patients with pleural effusion were often 
diagnosed to have neoplastic etiology. The mean age for 
malignancy was 53 years and for lymphoma 47 years. 
 
 
 
Fig 2: showing age distribution in TB, malignancy & 
lymphoma. 
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Gender distribution in TB pleural effusion (Fig 3) 
Among the 68 patients with tuberculous pleural effusion, 53 were 
male (78 %) and 15 were female (22%), with a male: female ratio 
of 3.5: 1. 
 
 
Fig 3: shows the gender distribution of TB pleural effusion. 
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Pleural fluid cellular characteristics (Table 5) 
The pleural fluid characteristics were analyzed and all patients had 
exudative pleural effusion based on Light’s criteria.  
80% of the patients had lymphocytic exudative pleural effusion 
and the predominant underlying disorders in these were 
tuberculosis and malignancy.  
24 patients had neutrophil predominant effusion and the aetiology 
in them was para-pneumonic effusions. A small subset of about 6 
patients had eosinophilic effusion.  
Cell counts Number of patients 
& percentages N (%) 
Lymphocyte 124 (80) 
Neutrophil 24 (15.58) 
Eosinophil 6 (3.89) 
Table 5: showing the cellular characteristics in pleural fluid 
Pleural fluid biochemical parameters (Fig 4 &5) 
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The pleural fluid biochemical parameters were analyzed with the 
etiology. Tuberculosis had the highest mean pleural fluid protein 
content, followed by malignancy and lymphoma. The pleural fluid 
lactate dehydrogenase (LDH) showed highest levels in malignancy, 
followed by lymphoma and Tuberculosis had the least.  
 
Fig 4: showing pleural fluid protein levels in TB, malignancy & 
lymphoma 
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Fig 5: showing pleural fluid LDH levels in TB, malignancy & 
lymphoma. 
 
Aetiology of pleural effusion (Fig 6) 
Among the 154 patients who were included in the study, 68 patients had 
tuberculosis, followed by 31 patients with malignancy which included 
primary from lung malignancy as well as other sites. Seven patients had 
lymphoma based on pleural biopsy. Four patients had effusion 
secondary to mesothelial tumour which included 2 benign mesothelial 
proliferations and 2 mesothelioma. Two cases with eosinophilic effusion 
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which was secondary to parasitic infestation-H.nana and Churg Strauss 
syndrome. In one patient, the cause for pleural effusion was fibrous 
tumour. Thirty six (23%) patients had no diagnosis despite pleural fluid 
studies and pleural histopathology.  
 
Fig6: showing the aetiology of pleural effusion 
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MTB yield on pleural tissue and fluid cultures: (Fig 7) 
All patients who underwent pleural fluid aspiration and pleural 
biopsy, the pleural samples were sent for cultures. 17 patients had 
pleural tissue culture growth and only 4 patients had pleural fluid 
growth for Mycobacterium tuberculosis among the 68 patients with 
tuberculous pleural effusion. Yield from AFB smear was 
extremely rare, occurring in only few patients. 
 
Fig 7: Showing pleural fluid and biopsy culture yield in the 
diagnosis of tuberculous pleural effusion. 
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Cytology yield in malignancy (Fig 8) 
Figure 6 shows the yield of cytology in diagnosis of malignancy. 
14 samples yielded the diagnosis of malignancy among the 31 
subjects (45%) with malignancy. 
 
Fig 8: showing the diagnostic yield of pleural fluid cytology  
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Pleural fluid biomarkers in pleural tuberculosis 
(Table 6, Fig 9, 10, 11) 
Adenosine deaminase (ADA): 
Adenosine deaminase was estimated in the pleural fluid samples. A 
cut off of 24U/L and above was taken as positive and a 2x2 table 
was used for analyzing the sensitivity and specificity. ADA had a 
sensitivity of 70.4% and a specificity of 71.1 %. The positive 
predictive value is 63.3 % and negative predictive value is 77.1%.  
The receiver operating curve (ROC) showed the area under the 
curve of 0.760 
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Figure 9: Showing the ROC curve for ADA 
Adenosine deaminase 2(ADA2):  
ADA2 is a subtype of ADA which was studied. Using a cutoff of 14U/L, 
ADA2 had a sensitivity of 78 % and a specificity of 62.7% for 
diagnosing pleural tuberculosis. The positive predictive value was 
60.9% and the negative predictive value was 79.2%. The ROC for 
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ADA2 showed the area under the curve of 0.706. The cut off 12.6U/L is 
taken with a sensitivity of 80% and sensitivity of 63%. 
 
Figure 10: showing ROC for ADA2 
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Interferon gamma:  
Using a cutoff of 2 IU/L, Interferon gamma had a sensitivity of 82.1 % 
with specificity of 86.2%. The positive and negative predictive values 
were 82.1 and 86.2 % respectively.  The ROC for Interferon gamma 
showed the area under curve of 0.881. Using a cut-off of 3.12 IU, the 
sensitivity and specificity are 80% and 87% respectively.  
Fig 11: showing the ROC for Interferon gamma 
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Biomarkers Sensitivity 
% 
Specificity
% 
AUC Cut-off 
U/L 
ADA 70.4 71.1 0.76 24 
ADA2 78 62.7 0.706 12.6 
Interferon gamma 82.1 86.2 0.881 3.12 
Table 6: showing the sensitivity, specificity, area under the 
curve (AUC) and cut-off values for biomarkers- ADA, ADA2, 
and Interferon gamma. 
Combination of biomarkers: 
The combination of biomarkers and their sensitivity and specificity 
were studied. When ADA was combined with ADA1/ADA ratio of 
≤0.42,  the sensitivity improved from 70.4% to 79.6% but the 
specificity declined from 71.1 % to 39.2%. 
The combination of ADA, ADA1/ADA ratio with Interferon 
gamma improved the sensitivity from 70.4% to 93.8% but it lacks 
specificity 35%. A combination of ADA and ADA2 had a better 
sensitivity of 80% but lacks specificity 62.7%. 
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The lymphocyte neutrophil ratio showed sensitivity of 87.5% but 
lacks sensitivity, 16.5%.  The combination of tests improved the 
sensitivity but failed to improve specificity. 
 
Biomarkers Sensitivity Specificity PPV NPV 
ADA+ ADA1/ADA     79.6     39.2      48.9     72.5 
ADA+ ADA1/ADA+ Int γ     93.8     35      53.6     87.5 
ADA+ ADA2      80     62.7      61.5     80.8 
 
Table 7: showing combination of biomarkers and their 
sensitivity, specificity, positive and negative predictive value in 
the diagnosis of TB pleural effusion. 
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Pleural fluid biomarkers in disease conditions: 
The pleural fluid biomarkers were compared in tuberculosis, 
malignancy and lymphoma.  The mean ADA levels in tuberculosis 
was high, it was low in malignancy and very high in 
lymphoma.ADA2 levels followed a similar trend.  
Interferon gamma in TB patients was high and was low in both 
lymphoma and malignancy. 
Biomarkers ADA 
U/L 
 
ADA1 
U/L 
ADA2 
U/L 
Interferon gamma 
IU 
Tuberculosis  47.0 15.9 34.7 18.3 
Malignancy 15.4 7.6 10.6 1.47 
Lymphoma 131.3 31.0 22.3 1.46 
Table 8: showing pleural fluid biomarkers levels in 
tuberculosis, malignancy and lymphoma. 
 
 
60 
 
6. Discussion: 
Demographic profile:  
During the period between May 2012 and July 2013, a total of 154 
patients were included in the study. The study population had a 
male predominance of 74%. The mean age of patients was 44.8 
years. Among the 154 patients, 146 patients had unilateral pleural 
effusion. Bilateral pleural effusion was seen in eight patients. The 
aetiology for bilateral pleural effusion was further analyzed and 
three patients had tuberculosis, one patient had adenocarcinoma, 
one patient had Sjogren’s syndrome and in three others, diagnoses 
were not conclusive. Tuberculous pleural effusion could also be 
bilateral (36). An article published in the year 1945 by E.Montushi, 
in his series of 601 patients, 6 percent of bilateral pleural effusion 
was due to tuberculosis(36).  
One patient with pleural effusion had HIV infection. Among the 
154 patients with pleural effusion, 37% of patients didn’t have 
sputum examination for acid fast bacilli (AFB) and two patients 
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were AFB positive. Sputum examination should be performed in 
suspected tuberculous pleural effusion. A study by Chaudhuri et 
al(37) looking at sputum examination in tuberculous pleural 
effusion showed a pickup rate of 22.22%. Another study looked at 
the yield of induced sputum in diagnosing tuberculous pleural 
effusion showed 52% yield on sputum cultures(38)(5) 
Among the 68 TB effusions, 53 were men and 15 were women. 
The male: female ratio was 3.5:1.  A higher male: female ratio of 
1.6:1(39)was also seen in a Spanish study. A scoring system 
framed for diagnosis of TB pleural effusion used male gender as 
one of the variable indicating that TB effusion is more among 
men(40). 
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Age distribution in disease condition:  
The mean age of patients who had TB pleural effusion was 39.13 
years. The minimum age with TB effusion was 17 years and 
maximum age 85 years. The mean age for malignancy and 
lymphoma are 53 years and 47 years respectively. The above data 
states that tuberculous pleural effusion is more common in the 
younger population and malignancy more common in the older 
population.  
Valdes et al(39) showed that tuberculous pleural effusion is more 
common in younger age group (age less than 40 years), 
malignancy is more common among age group of more than 50 
years and tuberculosis is the most common cause for pleural 
effusion followed by malignancy and heart failure. 
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Pleural fluid cellular characteristics: 
The pleural fluid characteristics showed a large proportion of 
patients about 80% had lymphocyte predominant pleural effusion 
fewer patients had neutrophilic effusion and a small proportion ; 
eosinophilic pleural effusions. The common causes for 
lymphocytic pleural effusion are; tuberculosis and malignancy and 
the commonest cause for neutrophilic effusion is parapneumonic 
effusion(41).  
Ten patients had eosinophilic pleural effusion. The causes of 
eosinophilic pleural effusion in our study were-  adenocarcinoma - 
two patients, T-cell lymphoma, tuberculosis, Churg-Strauss 
syndrome, Sjogren’s syndrome, H.nana infestation were the 
causative factors in one patient each, and in three patients the 
aetiology was uncertain. Krenke et al(42)in his study showed that 
malignancy is the commonest cause for eosinophilic effusion, 
followed by infections, unknown, post traumatic and 
miscellaneous causes. 
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Pleural fluid bio-chemical parameters:  
The pleural fluid biochemical parameters mainly pleural fluid 
protein and lactate dehydrogenase (LDH) were analyzed in each 
disease conditions. In our study, high protein levels with a mean of 
5.4mg/dL were seen in tuberculous pleural effusion followed by 
malignancy and lymphoma with a mean level of 4.9mg/dL and 
4.1mg/dL respectively.  
An Indian study revealed pleural fluid protein more than 3gm in 
94.34%(23) of tuberculous pleural effusion. In another study which 
looked at pleural fluid analysis in diagnosing TB pleural effusion, 
a combination of three parameters- pleural fluid protein ≥5g/dl, 
lymphocytes >80% and ADA > 45U/l , had a specificity of 100% 
and sensitivity of 34.9%(43) 
High levels of lactate dehydrogenase(LDH) levels are found in 
lymphoma and malignancy. Tuberculous pleural effusion had a 
mean LDH value 1209. A study by Ernam et al(44) showed that 
pleural fluid LDH levels were very high in parapneumonic 
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effusions followed by malignancy and then in tuberculous pleural 
effusion. Therefore, pleural fluid LDH can be elevated in many 
conditions including malignancy, lymphoma, tuberculosis and 
other conditions and is a non specific marker for making a specific 
diagnosis.  
Aetiology of pleural effusion: 
The aetiology of pleural effusion among the 154 patients was 
studied. Sixty eight patients (44%) had tuberculous pleural 
effusion, followed by 36 patients (23%) with pleural effusion of 
uncertain aetiology, followed by malignancy in 31 patients (20%). 
Seven patients had lymphoma; four patients had effusion 
secondary to mesothelial neoplasm - 2 benign mesothelial 
proliferations and 2 mesothelioma. A small subset of patients had 
effusion due to rare causes like Sjogren’s syndrome, Churg Strauss 
syndrome, parasitic infestation and fibrous tumour. The above data 
suggests that the common cause for pleural effusion is tuberculosis 
followed by malignancy. The observation by Valdes et al(39) 
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showed that tuberculosis is the common cause of pleural effusion 
in an area with high tuberculosis burden followed by malignancy 
and cardiac failure.  
MTB yield on pleural cultures: 
Among the 68 patents with tuberculous pleural effusion, 17 
patients (25%) had pleural biopsy culture growth and 4 patients 
(5%) had pleural fluid culture growth.   
A study showed that pleural biopsy culture had a better yield than 
pleural fluid culture, 62% versus 12% respectively(38) The British 
thoracic society guidelines quotes a 10-20% smear positivity rate 
on pleural fluid and 25-50% for pleural fluid cultures(41) 
An article by Trajman et al(26) showed that the yield of pleural 
fluid microscopy for AFB is <5% and pleural fluid cultures had a 
low sensitivity of 24-58%. Overall, pleural fluid culture is less 
useful and pleural biopsy culture had better yield. 
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Pleural fluid cytology yield in diagnosis of malignancy: 
Among the 154 patients, 122 pleural fluid samples were sent for 
cytological examination.  Fourteen samples were positive for 
malignant cells supporting the diagnosis of malignancy. Our study 
had a pleural fluid cytology yield of 45%.  
A retrospective analysis of 281 patients with malignant pleural 
effusion was studied and pleural fluid cytology yielded the 
diagnosis in 57.6% (45) Another study looked at the yield of 
pleural fluid cytology showed a yield of 65%(46) The yield of 
pleural fluid cytology is variable and largely depends on skill and 
interest of the cytologist and the tumour type(41) 
Pleural fluid biomarkers in pleural tuberculosis:  
In this study, we studied the role of pleural fluid biomarkers in the 
diagnosis of tuberculous pleural effusion. Pleural biopsy 
histopathology and cultures are the currently available gold 
standards for the diagnosis of tuberculous pleural effusion. The 
limitations for closed pleural biopsy are its complications like pain, 
68 
 
haemothorax, pneumothorax and very rarely death due to 
haemorrhage(7) To overcome these complications, we study the 
role of biomarkers in diagnosing TB effusion. In this study, we 
looked at three biomarkers-ADA, ADA2 and Interferon gamma. 
a. Adenosine deaminase (ADA):  
 
ADA is a biomarker which is found elevated in TB pleural 
effusion.  A cut off of ADA as 24 U/L was taken and the 
sensitivity and specificity were analyzed. The cutoff of 24 was 
taken as per the CMC biochemistry lab standards. The sensitivity 
of pleural fluid ADA in the study was 70.1% and specificity was 
71.1%. Which was low compared to other studies.  Kelam et al(47) 
showed a high sensitivity (90%) and a specificity of 50% in his 
study.  In a meta analysis of 63 studies reported, a sensitivity of 
92% and specificity of 90% with a cut off of 40u/l(21).  
The drawback of ADA is it lacks specificity. ADA can be elevated 
in many other conditions like parapneumonic effusions, empyema, 
and lymphoma, infections like brucellosis and in rheumatoid 
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arthritis thereby lacking specificity. ADA can be used as a 
screening tool because of its high sensitivity in tuberculous pleural 
effusion.  
 
b.   Adenosine deminase 2 (ADA2):  
 
ADA has two isoenzymes ADA1 and ADA2. ADA2 is found in 
macrophages and is released when stimulated by intracellular 
microorganisms. Our study revealed, ADA2 had a better sensitivity 
than ADA but it also lacks specificity. By analyzing the ROC with 
AUC of 0.706, the best cutoff value for ADA2 was 12.6U/L. Using 
a cutoff of 12.6U/L, the sensitivity of ADA2 was 80% and 
specificity was 63%.  Valdes et al(48) studied ADA isoenzymes 
and reported a sensitivity of 100% and specificity of 96% in TB 
pleural effusion.  
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c. Interferon gamma:  
 
Interferon gamma is released by activated CD4 +T lymphocytes. 
The cytokine is released when there is increased mycobactericidal 
activity by the macrophages. In our data, Interferon gamma had a 
sensitivity of 82.1% and a specificity of 86.2%.  Interferon gamma 
had a better sensitivity and specificity compared to ADA and 
ADA2. By analyzing the ROC, the best cut off for Inteferon 
gamma was 3.12IU. Using a cutoff 3.12 IU, the sensitivity was 
80% and specificity was 87%.  
A meta analysis of 22 studies on Interferon gamma showed a mean 
sensitivity of 89% and a mean specificity of 97%(21). A study 
looked at ADA and Interferon gamma levels in the diagnosis of TB 
pleural effusion. The sensitivity and specificity of ADA was 86% 
and 74% respectively whereas 100% sensitivity and 100% 
specificity for Interferon gamma(49). 
 In our study, Interferon gamma had a better sensitivity and 
specificity compared to ADA and ADA2.  
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d.Combination of biomarkers: 
 
A combination of biomarkers and its role in diagnosing TB pleural 
effusion was studied. When combining ADA and ADA1/ADA 
ratio, the sensitivity was 79.6% and specificity was 39.2%. When 
ADA with ADA1/ADA and interferon gamma was combined, the 
sensitivity improved to 93.8% but the specificity was only 35%.  
When ADA and ADA2 was combined, the sensitivity was 80% 
and specificity was 62.7%. In our observation, combination of tests 
improved the sensitivity but failed to improve specificity.  
Pleural fluid lymphocytosis is one of the feature of tuberculous 
pleural effusion(41). Pleural fluid lymphocyte neutrophil ratio was 
calculated; the ratio had a sensitivity of 87.5% and a specificity of 
16.5%.  
Valdes et at(48) studied the combination of ADA >47U/L , ADA2 
>40U/L and ADA1/ADA ratio <0.49 with a sensitivity of 100% 
and specificity of 97%. They concluded that ADA2 was a better 
marker than ADA. In effusions with high ADA levels; the ratio of 
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ADA1/ADA helps to differentiate tuberculous effusion from para-
pneumonic effusion, but fails to discriminate malignant effusions.  
A study by Keng et al(50) looked at combination of ADA ≥40 
IU/L and Interferon gamma ≥ 75pg/mL had 100% specificity.  
Burgess et al(51) studied the combination of ADA with 
lymphocyte neutrophil ratio and found a sensitivity of 88% and 
specificity of 95%.  
 
Pleural fluid biomarkers in disease conditions: 
The pleural fluid biomarkers-ADA, ADA1, ADA2 and interferon 
gamma are analyzed with diseases like tuberculosis, malignancy 
and lymphoma.  The ADA values are found high >100U/L in 
lymphoma and low in malignancy. In tuberculosis, the mean ADA 
level was 47U/L. A Meta analysis of 63 studies on ADA showed a 
sensitivity and specificity of 92% and 90% with cut off value 
40U/L(21).  
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ADA1 and ADA2 levels were elevated in lymphoma and 
tuberculosis and lower levels are seen in malignancy. Interferon 
gamma levels are elevated in tuberculosis.  
A combination of ADA >40U/L with Interferon gamma >3.12IU 
can improve the diagnostic yield in tuberculous pleural effusion.  
 
7. Limitations of the study: 
 
One of the limitations of this study is the small sample size. We 
recruited 154 patients and among them 68 patients had 
tuberculosis. Studies with large sample size are required to further 
analyze the role of biomarkers in tuberculous pleural effusion. 
Thirty six patients had inconclusive biopsy results and were 
labeled inconclusive. Further evaluation is required to find the 
cause for effusion and make correlation with the biomarkers.  
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            8. Clinical implications:  
The findings of the study have potential clinical implications: 
1. Among the three pleural fluid biomarkers, Interferon gamma 
has a good sensitivity and specificity which can be clinically 
utilized in diagnosing TB pleural effusion. 
 
2. A combination of ADA >40IU/L with interferon gamma 
>3.12IU can improve the diagnostic yield in tuberculous pleural 
effusion and these markers can be utilized in centers where 
there are limitation of resources for pleural biopsy and culture 
methods.  
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9. Conclusion:  
Tuberculous pleural effusion is one of the common causes for 
pleural effusion with a diagnostic challenge. The pleural fluid 
biomarkers, combination of tests and scoring system have an 
important role in diagnosing TB effusion but are not sufficient 
to replace the conventional gold standard methods for diagnosis. 
 
10. Areas of future work: 
 
a. A further study with large sample size is required to validate on 
pleural fluid biomarkers. 
b. A scoring system by combining biomarkers with clinical 
parameters is required to improve the specificity.  
c. Role of molecular diagnostic methods like Gene Xpert in TB 
pleural effusion. 
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I. PATIENT INFORMATION SHEET: 
Contact Information: 
Dr. A. Ashwin Oliver 
Department of Pulmonary medicine  
Christian medical college, Vellore- 632004  
Purpose of Subject information & Consent form:  
The purpose of this form is to inform you about this research 
study. If you sign this form, it means that you have agreed to take 
part in this study. The form describes the purpose, procedures, 
benefits, risks and side effects of the research study. It may contain 
words that you do not understand. Please ask the study doctor or 
personnel to explain any words or procedures that you do not 
clearly understand. You may also want to discuss this with your 
family and/or friends. You may refuse to take part or withdraw 
from this study at any time. This will not affect your medical care 
at the Christian Medical College (CMC) hospital. 
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Introduction: 
You are being asked to participate in this study because your 
doctor thinks you may have signs and symptoms of pleural 
tuberculosis (TB). This is a research project conducted by the 
Department of pulmonary medicine, Christian Medical College, 
Vellore, India. The research study evaluates the performance of a 
new simple, rapid test to detect TB in the pleura (lining of the 
lungs).   
As you may be aware, tuberculosis is an infection that mostly 
affects the lungs. However, TB can also affect other organs, 
including the lung lining, brain, abdomen, bone and joints, and 
lymph nodes and sometimes also several organs at the same time. 
TB is very common in India. It is a major cause of death and 
disability. Consequently, there is a need to develop and evaluate 
new or improved tests.  
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Purpose of the study: 
The purpose of the study is to compare the results of a new simple, 
rapid test for pleural TB against the best tests that are currently in 
use. We plan to perform the new as well as the currently available 
diagnostic tests in persons with suspected TB disease in their lung 
lining at the Christian Medical College Hospital, Vellore.  
Procedures: 
You will be asked to undergo the following tests, if your doctor 
suspects TB of the lung lining in you. All of these tests are done 
routinely outside of the research study as well. These tests include: 
Pleural tap and collection of a pleural tissue specimen:  
A trained, specialized physician (a chest doctor) will do the pleural 
tap and biopsy.  A needle will be inserted in between your ribs into 
the area between your chest wall and your lung (the pleural space). 
The doctor will draw 10 cc of fluid (2 teaspoons) from your chest 
and will take a small tissue sample from the inner lining of your 
87 
 
chest wall. Again this is a routine test if TB of the lung lining is 
suspected. 
The following tests will be done on the pleural fluid/biopsy 
sample: 
a. Smears to be examined under a microscope 
b. Culture to grow TB bacteria 
c. Pleural tissue sent for histo-pathological examination 
d. Left-over pleural fluid will be stored in a freezer for possible 
further testing 
Your pleural fluid specimen will be used to perform this new test, 
which is the only test that is not usually performed. 
Potential Risks & Discomforts: 
This study does not involve any new drugs or treatment. It involves 
adding additional tests for the diagnosis of TB to the tests currently 
used. The risks are mainly related to testing procedures (pleural tap 
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and biopsy) that are done routinely for the diagnosis of your 
condition outside of a trial as well.  The most common problems 
from a pleural tap include temporary soreness, bruising, and 
discoloration of the chest area where the needle is inserted. Some 
individuals may feel dizzy or faint during the pleural tap 
procedure. In rare cases there may be injury to the nerves, resulting 
in shoulder or neck pain. In very rare cases there may also be 
damage to the lung or abdominal organs resulting in bleeding or in 
lung collapse, which might necessitate surgery or placement of a 
chest tube. 
Potential benefits: 
Your participation may provide the medical community with 
information about whether a new, simple rapid test for pleural TB 
will work or not. You are assured the standard of care in terms of 
TB diagnosis whether you participate in this study or not. If you 
are found to have TB, you also will receive the standard of care. 
You will be referred to your usual health care provider at the CMC 
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hospital, where free treatment will be provided. A highly effective 
treatment for TB exists, and your health care provider will discuss 
this treatment with you, and initiate therapy following the 
guidelines of the Indian National TB Control Programme. If you 
are infected with HIV, you will also be referred for treatment. If 
other illnesses are identified, you will be referred for further 
evaluation and care. 
Potential Future Uses and Storage of the Samples: 
We are asking your permission to store a sample of your pleural 
fluid. Some of the fluid that is taken from your chest may be frozen 
and stored (banked) and used for future research related purposes 
for TB. The samples will not be sold, or used for any commercial 
purpose. They can be stored up to 2 years, after which the samples 
will be destroyed. It remains your right to ask for the destruction of 
your samples at any time. If you want your samples to be removed 
from the bank, you should contact Dr. A. Ashwin Oliver. 
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Confidentiality: 
All of the information that we obtain during this research will be 
kept confidential. No one other than the study investigators will 
know your identity from our files. The results of this research 
study may be presented at meetings or in scientific publications; 
however, your identity will not be disclosed in any of these 
presentations. As part of this study, we will request your 
authorization to access information from your medical files from 
the CMC hospital for your TB related evaluation, including details 
of other TB investigations (if any) and TB related outcomes. The 
ethics committee of CMC Vellore may also access your medical 
files. The samples that will be banked for future research purposes 
will not contain your name on them. They will simply have a code 
number and they will be stored in a freezer for 2 years. Only a few 
staff members of the research team will have access to the sample.  
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Voluntary participation & withdrawal:  
It is entirely your choice whether or not you participate in this 
research study. If you decide not to participate, your current and 
future medical care at the CMC will not be affected by this choice. 
You may decide to withdraw from this study at any time. Your 
participation in this study may be terminated by you, or your study 
investigators. 
Legal Rights: 
You are not waiving any of your legal rights by participating in 
this study or by signing this consent form. This includes, for 
example, the right to seek damages under law for any research 
related injury. 
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II. SUBJECT INFORMED CONSENT: 
1. I understand that this is a research study. 
2. I have read all the pages of the consent form. The research 
personnel have explained the information and procedures involved 
in the study. I have had the opportunity to ask questions and my 
questions have been answered satisfactorily. I have been given 
time to consider the information carefully and to decide whether or 
not to participate in this study. 
3. I have been informed that my participation in this study is 
entirely voluntary and that I may refuse to participate, or withdraw 
at any time, without any consequences to my ongoing and future 
medical care at this institution. 
4. I authorize the release of my medical records to the study 
investigators as well as the ethics committee of CMC Vellore for 
purposes of this study only. This authorization will be valid for a 
period of 5 years. 
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5. I understand that I will be given a copy of this informed consent 
form to keep for my own information, once it is signed. I have 
been informed that a copy of this consent form will be placed in 
my medical chart so that health care providers at this institution 
will know that I am participating in a study and what is involved. 
6. I understand that I do not give up any of my legal rights by 
signing this form nor am I freeing the investigators, sponsors, or 
the health establishment where the study takes place from their 
civil and professional responsibilities. 
7. I understand that the samples I provide will be used for the 
purpose of this research and other related research. 
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1. My signature below indicates that I voluntarily agree to take part 
in this study. 
________________________        _______________         
____________ 
Subject’s signature                      Name (in block letters)               
Date 
________________________   ______________              
_____________ 
Signature of Person                                                                           
Date 
Administering Informed Consent Name (in block letters) 
I confirm having met with the subject at the time of enrolment and 
have I have answered his/her questions about this study. 
Investigator or Project coordinator’s signature:  
Name (in block letters) Date 



age sex hno sput hiv sideffu serprot serldh pltc plpoly pllymph pleosin plprot plldh
72 1 293690F 3 2 1 4.9 243 4320 2 98 0 3.9 306
45 1 292928F 2 2 2 6.8 1134 1600 17 36 47 5.4 3716
59 1 286652F 2 2 1 7.3 629 220 6 94 0 1 1093
30 1 285212F 3 2 2 290 4 96 0 5 1108
55 1 287404F 2 2 1 7.1 1280 93 7 0 6.2 2312
53 1 289691F 3 2 1 9.2
35 1 283057F 2 2 1 7.6 1900 24 57 19 4.9 485
28 1 287346F 2 2 1 7.4 839 4000 3 97 0 5 519
68 1 285608F 2 2 1 850 5 95 0 5.5 458
31 2 290883F 2 2 1 6.7 918 1100 12 88 0 5.4 5012
28 2 695079D 2 2 2 7.3 1560 18 82 0 4.8 369
31 2 300468F 2 2 2 5.7 50 26 74 0 1.3 124
57 1 293743F 2 2 1 2100 6 94 0 5.1 3393
31 1 178072F 2 2 3 8.1 35 76 24 0 5.8 1183
48 1 299377F 3 2 2 6.8 528 1500 19 71 10 6.1 4734
59 1 684173D 2 2 1 4.8 485
54 1 704400A 3 2 1 7.8 348 3950 4 96 0 5.9 545
24 2 331382F 2 2 2 8.5 407 960 3 97 0 6 998
32 1 332849F 2 2 2 5.5 2319 4800 2 98 0 3.6 5200
64 1 318381F 2 2 1 5.1 1800 53 47 0 0.7 96
41 1 329704F 2 2 1 7.6 3300 3 97 0 5.7 523
49 1 263095F 3 2 1 7.6 353 1300 2 98 0 5.6 530
53 1 337272F 3 2 1 320 12 87 1 5.4 1071
41 1 303063F 2 2 1 7.8 3200 3 97 0 4.7 245
17 1 319358F 2 2 2 8.1 480 25 75 0 5.6 1592
52 1 340889F 3 2 2 4800 2 98 0 6 517
65 1 138476F 2 2 1 9.1 3600 2 98 0 6.5 344
29 1 337053F 3 2 2 9.7 544 6500 5 95 0 6.4 862
52 2 337289F 2 2 1 7.9 6400 2 98 0 5.4 194
55 1 340493F 2 2 2 7.5 1668 3350 82 18 0 5.5 1400
23 1 323129F 3 2 1 800 52 48 0 6.1 881
61 1 825833D 2 2 2 8.3 130 15 85 0 2 184
57 1 352889F 2 2 1 7.4 452 1400 7 92 1 5.2 706
44 1 007118F 1 2 1 6 555 1100 20 80 0 4.3 554
22 2 317887F 2 2 2 7.8 17947 92 8 0 5.6 6850
85 1 333461F 2 2 2 6.5 574 960 2 98 0 4.3 816
74 1 232062B 3 2 2 7.5 394 640 66 28 6 1.7 7640
55 1 347626F 2 2 2 7.1 364 280 80 18 2 5.4 3889
66 1 310685F 3 2 1 960 9 91 0 4.8 1933
17 2 355737F 3 2 1 7.1 378 2500 2 98 0 6.4 284
74 1 518121C 3 2 1 7.3 816 15200 81 19 0 4.9 1015
38 1 398575F 3 2 1 1600 4 95 1 3.2 303
30 1 388888F 2 2 1 7.5 1700 1 99 0 5.9 545
42 2 391131F 3 2 2 350 19 80 1 5.2 416
37 1 389668F 3 2 2 7.9 2900 3 96 1 5.3 497
51 2 061675F 3 2 1 5.8 2200 94 6 0 3.2 713
44 1 377109F 3 2 2 8500 2 98 0 5.8 472
49 2 441218F 2 2 1 7.7 457 730 2 97 1 4.6 468
40 1 446006F 2 2 1 9 605 1800 92 7 1 6.6 10600
58 1 824551D 2 2 1 6.8 640 4 96 0 3.8 373
35 2 369998F 2 2 1 486 1800 3 97 0 6 523
66 1 041887F 3 2 1 5.2 322 13500 2 98 0 3.6 295
23 1 440952F 2 2 3 8.5 502 210 8 92 0 6.1 1412
46 2 032309F 2 2 1 8.1 1920 1 99 0 3.9 125
33 1 444586F 2 2 1 8.1 457 2850 5 47 48 5.4 1189
53 1 348955D 2 2 1 6.1 23100 87 10 3 5.7 1497
22 2 506081F 2 2 2 8.5 1280 6 94 0 6.3 1020
56 2 394500F 2 2 1 7.4 1325 700 10 88 2 5.4 709
20 1 403472F 2 2 2 7 1510 80 20 0 4.5 2447
18 2 429125F 3 2 2 7.4 451 5201 12 88 0 4.9 886
61 1 417737F 2 2 1 2200 5 95 0 5.5 438
23 1 440952F 2 2 3 8.5 502 3800 2 98 0 5.1 2528
32 1 388375F 2 2 2 7.9 566 2100 14 14 72 7 383
57 1 491706 2 2 2 6.1 620 16 84 0 4.2 406
30 2 341710C 3 2 2 8 335 1600 10 83 7 5.7 341
60 1 122821C 2 2 1 7.8 536 200 16 83 1 3.3 315
35 1 377659F 3 2 2 1500 2 98 0 6 487
58 1 381352F 2 2 2 7.1 1700 32 58 0 3.2 443
60 1 414379F 3 2 1 3000 22 78 0 4.8 1006
64 1 405121F 2 2 1 7.9 447 620 30 70 0 5.2 1565
29 1 337053F 3 2 2 9.7 544 185 5 95 0 6.4 1597
67 2 417916F 2 2 1 2550 4 96 0 3.8 222
28 1 445582F 2 2 2 9.1 8000 2 98 0 6.3 450
39 1 442332F 2 2 1 7.5 2915 8 92 0 5.3 638
29 1 449900F 2 2 1 7.6 12800 2 93 5 5.8 902
29 1 388713F 2 2 1 8.6 500 93 7 0 5.1 4025
50 1 449906F 3 2 1 7.3 338 260 2 98 0 4.7 437
45 2 425278F 2 2 1 8.4 110 20 80 0 5.1 1501
76 1 417269F 2 2 1 6.8 726 1050 18 82 0 4.1 1689
38 2 553883C 2 2 2 7 362 2200 2 98 0 5.2 1034
55 2 372239F 3 2 2 7.4 1100 18 81 1 6.7 9070
24 1 380645F 2 2 2 7.5 5.5 411
28 1 369267F 3 2 1 8.9 6400 2 98 0 6.7 718
73 1 380898F 3 2 1 6.2 3000 7 92 1 10.8 2037
59 1 457372F 2 2 1 140 14 84 2 5.1 537
48 1 537072D 3 2 1 10.4 403 2500 2 98 0 4 270
28 1 464552F 2 2 2 8.7 7550 1 99 0 7.3 728
30 1 469267F 3 2 2 4300 1 99 0 5.9 744
50 1 459399F 2 2 1 4300 2 90 8 6 525
39 1 459744F 2 2 1 8.2 388 1800 85 15 0 5.3 2910
46 1 850799C 3 2 1 7.5 515 2700 3 97 0 4.8 265
25 2 455531F 3 2 1 5.5 821 400 28 70 2 1.4 425
62 1 254989F 3 2 2 6.9 388 1600 18 82 0 4.4 2164
42 1 973540C 2 2 2 8.4 5100 2 98 0 5.5 361
58 1 253266F 2 2 1 6.8 525 650 16 84 0 3.6 184
50 1 227500D 2 2 3 7 453 550 15 85 0 3.8 942
65 1 172773F 3 3 2 5.6 505 1725 3 97 0 5 730
31 2 253391F 3 2 2 7.2 290 304 60 40 0 4.3 223
63 2 257398F 2 2 2 7.1 3830 6 94 0 5.7 437
58 2 249748F 3 2 2 8 417 150 3 97 0 5.1 245
25 2 261745F 2 2 1 8.5 516 6.5 959
59 1 263695F 3 2 1 3000 1 99 0 4.9 396
48 2 262051F 3 2 2 7.1 394 5 95 0 4.8 1021
57 2 269566F 2 2 1 7.5 1470 250 2 98 0 4.1 1069
70 2 337930D 3 2 1 420 15 85 0 6.7 840
61 1 257798F 2 2 1 2010 1 99 0 5.6 392
48 1 067835D 2 2 2 7.5 353 2600 2 30 68 6.1 390
34 1 284594F 3 2 1 7.4 2250 47 53 0 5.6 293
62 1 274325F 3 2 2 5.9 728 4000 1 99 0 3 355
39 1 455689F 2 1 2 8.7 600 2 98 0 6 610
61 2 464537C 2 2 1 7.7 3400 1 99 0 6.1 240
46 1 887906C 3 2 3 5.8 407 780 2 98 0 2.9 35
55 2 314312D 3 2 2 7.4 360 480 10 90 0 5.5 244
28 1 409057F 2 2 2 8.7 215 5 95 0 5.8 590
55 1 479180F 2 2 1 7.2 4.5 748
34 1 292163F 1 2 1 7.7 15910 98 2 0 0.9 19180
57 1 486392F 2 2 2 320 4 96 0 9.1 365
63 1 610765F 2 2 1 7.9 4850 4 96 0 5.5 443
27 2 615467F 3 2 1 630 5 95 0 5.3 578
70 2 605878F 2 2 3 8.1 150 17 83 0 5.6 205
46 1 612692F 2 2 2 7.3 390 95 5 0 5.4 4090
74 1 609499F 2 2 2 7.1 410 60 40 0 4.5 1905
34 1 609189F 2 2 1 2220 3 97 0 5 677
35 1 491469F 3 2 1 7.8 698 1500 1 99 0 4.4 873
71 1 602627F 2 2 2 3700 6 15 79 6.4 957
34 2 186669F 3 3 1 8.2 602 2100 1 99 0 6.2 714
19 1 184193F 3 2 1 8.7 502 650 4 96 0 4.1 553
24 1 194133F 2 2 2 8.6 684 1920 2 98 0 5.9 359
67 1 196045F 3 2 1 5200 5 95 0 5.8 474
38 2 197355F 2 2 1 8.3 4200 2 98 0 5.3 205
75 2 000048F 3 2 1 7.4 665 480 8 92 0 5.1 695
20 1 200765F 2 2 1 8 1920 4 96 0 4.8 360
57 1 199061F 3 2 2 7.8 1120 4 96 0 5.2 441
31 1 613792C 2 2 2 7.6 3000 1 99 0 4.8 647
20 2 209291F 3 2 1 8.5 441 1280 91 9 0 6.5 4495
47 1 468772D 2 2 1 7.2 240 2880 3 97 0 6.3 250
18 1 133159F 2 2 1 8.4 475 1600 2 98 0 5.3 2258
28 2 703830A 3 2 3 11.9 270 1050 4 36 60 9.9 275
51 1 219598F 2 2 1 8.2 348 2600 95 5 0 6.2 11260
29 1 218950F 2 2 2 7.2 554 6100 98 2 0 4.7 2999
21 1 841594D 2 2 2 5.3 439 1400 1 99 0 2.9 170
16 1 221380F 3 2 1 6.8 396 4850 96 4 0 4.5 13700
42 1 220865F 2 2 1 8.3 566 2600 2 70 28 5.3 336
61 1 144552F 2 2 1 6.9 520 1100 6 30 64 5.4 432
48 1 118710F 3 2 2 8.2 602 950 4 96 0 4.4 321
41 1 961357D 2 2 1 6.6 303 6400 2 98 0 5.4 535
51 1 228328F 2 2 2 6.8 463 2700 18 77 5 4.7 2359
20 1 223229F 3 2 1 6.6 271 7200 1 99 0 5.2 671
42 2 233797F 2 2 2 8.1 547 4860 2 98 0 5.3 683
35 1 234685F 3 2 1 6.2 677 1650 30 70 0 3.6 958
43 2 224605F 2 2 1 7.2 180 16 84 0 4.4 782
50 1 219604F 2 2 1 7.4 309 1210 1 99 0 5.8 289
59 1 250607F 3 2 3 6 368 25 17 78 5 3.9 265
22 1 234313f 2 2 1 7.4 357 16000 75 25 0 6.1 824
ada ada1 ada2 int plbiop plflcul biopcul cyto diag diagspe
44 11.9 32.1 15.4 1 2 2 2 1 Tuberculosis
347.5 73.1 274.4 1.86 2 2 2 2 3 T cell lymphocytic lymphoma
12 3.4 8.6 1 2 2 2 1 2 Adenocarcinoma
80.7 19.2 61.5 30 1 2 2 3 1 Tuberculosis
12.4 8.4 4 1 3 2 2 2 4 Inconclusive
60.5 4.3 1 2 2 3 1 Tuberculosis
10 5.7 4.3 1 2 2 2 1 2 Adenocarcinoma
13 1 2 2 2 2 3 T cell lymphoma
9 30 3 2 2 2 4 Inconclusive
4.8 1 2 2 2 1 2 Adenocarcinoma
10 6.8 3 2 2 2 4 Inconclusive
0.9 1 3 2 2 2 4 Inconclusive
14.8 1 2 2 2 1 2 Adenocarcinoma
86.9 17.6 69.3 9.3 1 2 2 2 1 Tuberculosis
19.1 8.4 2 2 2 2 2 Adenocarcinoma
7.1 2.7 4.4 1 2 2 2 1 2 Adenocarcinoma
44.4 16 28.4 6.8 2 2 2 1 Tuberculosis
71.1 36.9 34.2 30 1 2 2 2 1 Tuberculosis
331 134 197 1 2 2 2 2 3 T-cell lymphoma
10.9 4.7 6.2 1.54 3 2 2 2 4 Inconclusive
37.6 17 20.6 30 1 2 1 2 1 Tuberculosis
40.2 12.9 27.3 30 1 2 2 2 1 Tuberculosis
12.4 4.1 8.3 1 3 2 2 2 4 Inconclusive
1.99 3 2 2 2 4 Inconclusive
42.9 0.3 42.6 30 1 2 1 3 1 Tuberculosis
14.1 23.5 1 2 2 3 1 Tuberculosis
23.4 10.9 12.5 1 3 2 2 2 4 Atypical mesothelial proliferation
18.9 30 1 2 1 2 1 Tuberculosis
20 1.58 3 2 2 3 4 Inconclusive
28.7 8.9 19.8 1.28 2 2 2 2 2 Small cell carcinoma
29 14.2 43.2 9.8 1 2 2 2 1 Tuberculosis
2 1.4 0.6 1 3 2 2 2 4 Inconclusive
14.1 11.7 2.4 1 3 2 1 2 1 Tuberculosis
25.8 1.5 24.3 1 2 2 3 1 Tuberculosis
103.6 51.4 52.2 30 3 1 2 3 1 Tuberculosis
19.7 11.7 8 12.6 1 2 1 2 1 Tuberculosis
27.9 9.4 18.5 1 2 2 2 2 2 Malignancy
26.4 10.9 15.5 1 3 2 2 3 4 Inconclusive
22.2 13.2 9 1.3 3 2 2 2 4 Atypical mesothelial proliferation
27.4 13.4 14 9 1 2 2 2 1 Tuberculosis
16.9 1.2 15.7 1.5 2 2 2 2 2 Carcinoma
5.6 2.6 3 1 3 2 2 2 4 Inconclusive
31.1 16.3 14.8 30 1 2 2 2 1 Tuberculosis
6.7 6 0.7 1 2 2 2 1 2 Adenocarcinoma
10.4 10.4 0 1 2 2 2 1 2 Adenocarcinoma
5.2 1 1 2 2 2 2 Adenocarcinoma
11.3 8.1 3.2 8.23 1 2 2 2 1 Tuberculosis
4.9 1 2 2 2 1 2 Adenocarcinoma
65.5 51 14.5 1 3 2 2 2 4 Inconclusive
9.1 4.4 4.7 1 3 2 2 2 4 Inconclusive
17.8 28.6 1 2 1 2 1 Tuberculosis
152.7 36.6 116.1 1 2 2 2 2 3 Non-Hodgkin's lymphoma
38.3 36.7 1.6 30 1 2 1 2 1 Tuberculosis
20.1 28.7 1 2 1 2 1 Tuberculosis
12.6 12.6 0 1 3 2 2 2 4 Inconclusive
75.2 49.4 25.8 1 3 2 2 2 4 Inconclusive
19.4 30 1 2 1 2 1 Tuberculosis
8.6 3.1 5.5 1 2 2 2 2 2 Adenocarcinoma
132.3 23.3 109 30 3 2 1 3 1 Tuberculosis
20.4 30 1 2 2 3 1 Tuberculosis
164.7 9.8 154.9 14.7 3 2 2 2 1 Tuberculosis
63 37.7 25.3 30 1 2 1 2 1 Tuberculosis
19.8 19.8 0 1 3 2 2 2 4 Churg Strauss syndrome
9.9 3.66 1 2 2 2 1 Tuberculossis
118 36.7 81.3 30 1 2 2 2 1 Tuberculosis
8.3 20.3 3 2 2 3 4 Inconclusive
23.6 17.9 5.7 1 1 2 1 3 1 Tuberculosis
8.8 10.7 1 1 2 2 2 1 Tuberculosis
40.6 12.3 28.3 1 2 2 2 2 2 Adenocarcinoma
37.4 12.8 24.6 30 1 2 2 2 1 Tuberculosis
38.3 14.3 24 30 1 2 1 2 1 Tuberculosis
41.1 4 37.1 1 2 2 2 2 2 Adenocarcinoma
17.2 11.8 5.4 30 1 2 2 2 1 Tuberculosis
6.8 5.8 1 1 2 2 2 3 2 Adenocarcinoma
14.9 14.9 0 3.24 1 2 2 2 1 Tuberculosis
84.2 36.4 47.8 4.88 1 1 2 3 1 Tuberculosis
3.1 2 1.1 1 2 2 2 2 2 Adenocarcinoma
51.4 12.6 38.8 1 2 2 2 1 2 Poorly differentiated carcinoma
46.9 7.4 39.5 1 2 2 2 1 3 Adenocarcinoma
39.3 14.2 25.1 28.8 1 2 2 3 1 Tuberculosis
13.7 10 3.7 1 2 2 2 1 2 Adenocarcinoma
19.9 7.3 12.6 5.4 1 2 2 2 1 Tuberculosis
33.9 10.8 23.1 8.09 1 2 1 3 1 Tuberculosis
2.5 6.3 1 2 2 2 2 2 Adenocarcinoma
3.6 2 1.6 1 3 2 2 2 4 Probable mesothelioma
18.2 5.5 12.7 3 1 2 2 3 1 Tuberculosis
12.2 15.2 21.9 1 2 1 2 1 Tuberculosis
21.6 23.7 18.2 1 2 1 2 1 Tuberculosis
3.8 6.7 1 2 2 2 1 2 Adenocarcinoma
23.8 29.2 30 1 2 2 2 1 Tuberculosis
2 4.7 1 3 2 2 3 4 Inconclusive
5.7 2.7 3 1 3 2 2 3 4 Inconclusive
7.9 33.7 1 2 2 2 1 2 Adenocarcinoma
22.7 20.3 3 2 2 2 4 Inconclusive
13.6 5 8.6 1 3 2 2 2 4 Inconclusive
11.3 11.3 0 1 2 2 2 1 2 Adenocarcinoma
92.3 25.8 66.5 30 1 2 2 2 1 Tuberculosis
22.9 4.6 18.3 4.6 3 2 2 3 4 Inconclusive
4.1 3.6 3 2 2 2 3 Metastatic carcinoma+ pulm TB-TBLB
4.9 1.64 1 2 2 2 1 Tuberculosis
13.9 30 1 2 1 3 1 Tuberculosis
12.8 3.4 9.4 1 3 2 2 2 4 Inconclusive
13.1 8.3 4.8 1 3 2 2 2 4 Inconclusive
61.6 7.5 54.1 17.3 1 1 2 2 1 Tuberculosis
15.9 3.4 12.5 1 2 2 2 2 2 Adenocarcinoma
37.1 9.2 27.9 3.28 3 2 2 2 4 Inconclusive
13.2 5.7 7.5 1 3 2 2 2 4 Inconclusive
23.9 4.1 19.8 13 1 2 2 2 1 Tuberculosis
17.8 2.9 14.9 1 3 2 2 3 3 Non-Hodgkin's lymphoma
42.4 14.2 28.2 30 1 2 2 3 1 Tuberculosis+ HIV infection
5.7 1.7 1 2 2 2 1 Tuberculosis
3.5 4.7 1 3 2 2 3 4 Inconclusive
6.6 4.6 2 1 3 2 2 2 4 Benign mesothelial proliferation
20.3 10.6 9.7 1.9 1 2 2 3 1 Tuberculosis
7.9 11.9 1 3 2 2 2 4 Inconclusive
56.9 9.6 47.3 12.6 1 3 1 Tuberculosis
17.4 7.2 10.2 1 3 2 2 3 4 Inconclusive
43.9 15.8 28.1 24.1 1 2 2 2 1 Tuberculosis
17.6 30 1 2 2 2 1 Tuberculosis
9.5 3 6.5 1 3 2 2 2 4 Inconclusive
44.9 12.1 32.8 1 3 2 2 2 4 Inconclusive
83.2 33.8 49.4 30 1 2 2 2 1 Tuberculosis
32.1 13.4 18.7 1 1 2 2 2 1 Tuberculosis
11.8 6 5.8 1 2 2 2 2 2 Malignancy
39.7 14.5 25.2 1.01 1 2 2 2 1 Tuberculosis
65.1 12.4 52.7 20.6 2 2 3 4 Inconclusive
65.9 13.3 52.6 1 1 2 2 3 1 Tuberculosis
37.7 5.7 32 30 1 2 2 3 1 Tuberculosis
45.9 7 38.9 30 1 1 Tuberculosis
14.1 3.6 10.5 1 3 2 2 2 4 Aspergilloma?
12.1 15.7 1.79 2 2 2 2 2 Non-small cell carcinoma
67.5 9 58.5 30 1 2 2 2 1 Tuberculosis
11.2 3.1 8.1 1 1 2 2 2 1 Tuberculosis + small cell carcinoma
48.3 10.8 37.5 27.7 1 2 2 2 1 Tuberculosis
248.9 43.3 205.6 30 3 2 2 2 4 Tuberculosis
31 4.3 26.7 1 3 2 2 2 4 Inconclusive
78.7 13.6 65.1 30 1 2 2 3 1 Tuberculosis
13.7 2 11.7 1 3 2 2 2 1 Sjogren's syndrome+ Disseminated TB
122.2 31.8 90.4 1.29 3 2 2 2 4 Clostridium empyema
60.4 8.3 52.1 1 3 2 2 2 4 Left Pyogenic hydropneumothorax
10.5 2 8.5 1.4 2 2 2 2 3 Lymphoma
86.4 13.9 72.5 1 3 2 2 2 4 Right complicated parapneumonic effusion
14.5 2.5 12 1 3 2 2 2 4 Inconclusive
14.1 2.3 11.8 1 3 2 2 2 4 Eosinophilic effusion- Probable secondary to H.nana
9.9 2.1 7.8 1 3 2 2 2 2 Inconclusive
57.7 7.1 50.6 30 1 2 2 2 1 Tuberculosis
17.4 6.4 11 1 2 2 2 2 2 Adenocarcinoma
23.2 8.7 14.5 30 1 2 2 2 1 Tuberculosis
8.7 2.1 6.6 1 2 2 2 2 2 Adenocarcinoma
12.9 6.2 6.7 1.33 2 2 2 2 3 Lymphoma
12.2 9.5 2.7 6.68 3 2 2 2 2 Fibrous tumour
67.1 5.5 61.6 3.45 1 2 2 2 1 Tuberculosis
9.8 2 7.8 1 3 2 2 2 4 Inconclusive
30.8 6.6 24.2 1 3 2 2 2 4 Inconclusive
